TABLE 1.
Patient characteristics and grafting details
| Patient No. | Age at cryopreservation | Prior chemo‐therapy | Disease | Uterus affected by treatment | Requires gestational carrier | Freezing at our institution | Year of cryopreservation | Duration of cryopreservation | Year of transplantation | Graft sites a |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 17.8 | Yes | Non‐Hodgkin’s lymphoma | TBI | Y | 1996 | 10.5/12.1 | 2006/2008 | A+P+O/A+P+O | |
| 2 | 19.0 | Sarcoma soft tissue | Y | 2004 | 14.2 | 2018 | A+P | |||
| 3 | 19.5 | Benign ovarian cysts | N | 2000 | 9.1/11.6 | 2011/2012 | A/A+P | |||
| 4 | 21.6 | Cervical cancer | PRT | Yes | Y | 2009 | 3.6/5.6 | 2012/2014 | A+P/A+P | |
| 5 | 22.0 | Hodgkin’s lymphoma | N | 2009 | 6.7 | 2015 | A+P | |||
| 6 | 22.0 | Yes | Ewing’s sarcoma | Y | 2014 | 3.1 | 2017 | A+P | ||
| 7 | 22.2 | Endometriosis | Yes | N | 1997 | 13.3/16.6/18.2 | 2010/2013/2015 | A+P/A+P/A+P | ||
| 8 | 23.3 | Yes | Hodgkin’s lymphoma | Y | 2013 | 6.7 | 2020 | A+P+O | ||
| 9 | 23.5 | Non‐Hodgkin’s lymphoma | TBI | Y | 2009 | 3.9 | 2013 | A+O | ||
| 10 | 24.7 | Granulosa cell tumor | Y | 2003 | 7.3/9.4 | 2010/2012 | A+P/A+P | |||
| 11 | 25.0 | Wegener’s granulomatosis | Y | 1997 | 16.7 | 2014 | P | |||
| 12 | 25.4 | Hodgkin’s lymphoma | N | 2011 | 8.7 | 2019 | A+P+O | |||
| 13 | 25.5 | Autoimmune polyarteritis | Y | 2005 | 13.1 | 2019 | A +P+O | |||
| 14 | 26.1 | Pelvic sarcoma | PRT | Yes | Y | 2005 | 7.8 | 2013 | A | |
| 15 | 26.1 | Yes | Hodgkin’s lymphoma | N | 2000 | 12.5 | 2012 | P | ||
| 16 | 26.9 | Hodgkin’s lymphoma | Y | 2009 | 10.6 | 2019 | A+P+O | |||
| 17 | 28.1 | Yes | SLE, lupus nephritis | Y | 1996 | 11.8 | 2008 | A+O | ||
| 18 | 29.0 | Yes | Anti‐NMDA encephalitis | N | 2015 | 2.6 | 2018 | A+P | ||
| 19 | 30.0 | Cervical cancer | Yes | N | 2017 | 1.9 | 2018 | A | ||
| 20 | 30.7 | Wegener’s granulomatosis | Y | 1999 | 8.3/10.0 | 2007/2008 | A+P+O/P+O | |||
| 21 | 31.0 | Yes | Hodgkin’s lymphoma | Y | 2011 | 4.7 | 2016 | A+P | ||
| 22 | 31.0 | Neuroendocrine tumor of cervix | Yes | Y | 2013 | 2.2/3.6 | 2015/2017 | A/A | ||
| 23 | 31.4 | Cervical cancer | PRT | Yes | Y | 2011 | 2.4/3.8 | 2013/2014 | A/A | |
| 24 | 31.7 | Yes | Hodgkin’s lymphoma | Y | 2010 | 4.1/6.3 | 2014/2016 | A+P/A+P | ||
| 25 | 31.9 | Yes | Non‐Hodgkin’s lymphoma | TBI | Y | 2005 | 3.7/6.4 | 2008/2011 | A+P+O/P+O | |
| 26 | 32.6 | Cervical cancer | PRT | Yes | Y | 2011 | 1.8 | 2012 | P+O | |
| 27 | 32.9 | Ewing’s sarcoma | Y | 2019 | 4.3 | 2019 | A+P | |||
| 28 | 33.0 | Cervical adenocarcinoma | Yes | Y | 2010 | 5.8 | 2016 | A+P | ||
| 29 | 33.0 | Cervical cancer | Yes | N | 2007 | 10.4 | 2018 | A+P | ||
| 30 | 33.5 | Cervical cancer | Y | 2016 | 2.1/3.6 | 2018/2019 | A/A | |||
| 31 | 34.1 | Hodgkin’s lymphoma | Y | 2015 | 3.9 | 2019 | A+P+O | |||
| 32 | 34.2 | Endometrial cancer | Yes | N | 2010 | 3.2 | 2013 | A+P | ||
| 33 | 35.7 | Endometriosis | Y | 1997 | 11.5 | 2008 | A+P+O | |||
| 34 | 36.0 | Yes | Non‐Hodgkin’s lymphoma | Y | 2014 | 3.3/4.4 | 2017/2018 | A+P/P | ||
| 35 | 36.0 | Endometrial sarcoma | Yes | Y | 2014 | 3.0 | 2017 | A+P | ||
| 36 | 37.1 | Breast cancer | Y | 2005 | 7.6/10.4 | 2013/2015 | P+O | |||
| 37 | 37.4 | Premature ovarian insufficiency b | N | 2001 | 7.1 | 2009 | A+P+O | |||
| 38 | 38.4 | Breast | N | 2017 | 2.0 | 2019 | A+P+O | |||
| 39 | 39.0 | Cervical cancer | Y | 2016 | 1.5/2.7 | 2017/2019 | A+P | |||
| 40 | 40.7 | Desmoid tumor | Y | 2016 | 3.1 | 2019 | A+P |
Abbreviations: N, No; PRT, pelvic radiotherapy; TB, total body radiation; Y, Yes.
a
A=abdominal wall, P=pelvic side wall, O=ovary.
b
Patient 19 had tissue frozen interstate and the indication appears uncertain and documented as premature ovarian insufficiency.